A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults

An intranasal COVID-19 vaccine, DelNS1-based RBD vaccines composed of H1N1 subtype (DelNS1-nCoV-RBD LAIV) was developed to evaluate the safety and immunogenicity in healthy adults. We conducted a phase 1 randomized, double-blinded, placebo-controlled study on healthy participants, age 18–55 and COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruiqi, Chan, Kwok-Hung, Wang, Pui, Zhou, Runhong, Yau, Henry Kwong-Chi, Wong, Creany Ka-Wai, Au, Meena Wai-Lam, Tam, Anthony Raymond, Ng, Chi-Tao, Lou, Matthew Kwok-Chung, Liu, Na, Huang, Haode, Deng, Shaofeng, Tam, Rachel Chun-Yee, Liu, Ying, Long, Teng, Tsoi, Hoi-Wah, Ng, Miko K. W., Cai, Jian-Piao, To, Kelvin Kai-Wang, Yuen, Man-Fung, Chen, Zhiwei, Chen, Honglin, Yuen, Kwok-Yung, Hung, Ivan Fan-Ngai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143096/
https://www.ncbi.nlm.nih.gov/pubmed/37112634
http://dx.doi.org/10.3390/vaccines11040723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143096/
https://www.ncbi.nlm.nih.gov/pubmed/37112634
http://dx.doi.org/10.3390/vaccines11040723

Ejemplares similares